Utility Before Profitability: The Evolving Evidence Paradigm For Molecular Diagnostics
The standards needed for reimbursement of molecular diagnostics are changing – especially with respect to genomics-based tests, with their potential impact on public health with respect to screening, prevention, and measuring response to treatment, as well as cost. As the complexity of the assay development and launch process has grown, so too has the emphasis on evidence and clinical effectiveness, as well as the importance of finding better ways to align test coding and reimbursement with clinical value. But a lack of coordination across agencies and commercial players makes an assessment of the impact of any changes on evidence demands problematic.
You may also be interested in...
The recent launch of several noninvasive gene-based tests for Down syndrome and other fetal chromosomal abnormalities is poised to upend current prenatal screening practices and potentially usher in a new, multibillion-dollar market opportunity in the process. These new tests employ next-generation gene sequencing, along with advanced, risk-based computer algorithms, to detect and characterize fetal genetic abnormalities using the DNA present in a maternal blood sample. And because they are actually able to “interrogate” the DNA, they represent a huge technological advance over the current standard-of-care for prenatal screening.
With low-cost whole genome sequencing on the horizon, issues around acquiring and assessing large data sets of sequence information are front and center. The value proposition is also shifting, from the means of acquiring data to their interpretation. But finding a sustainable business model around data analysis and clinical services is far from straightforward.
A variety of new players have become active dealmakers around personalized medicine diagnostics tests and services. One way to put these deals in context is to view the acquired assets through the lens of how they are to be deployed. To a large extent, the transactions are being driven by the interests of drugmakers, which are seeking new tools to assist them in clinical trials, thus creating more opportunity for the acquirers to offer clinical development services.